EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab
Authors
Keywords
Colorectal cancer, Cetuximab, PTEN, PIK3CA
Journal
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume 140, Issue 5, Pages 737-748
Publisher
Springer Nature
Online
2014-03-04
DOI
10.1007/s00432-014-1626-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes
- (2013) George Pentheroudakis et al. BMC CANCER
- PIK3CA, BRAF , and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17
- (2013) Christos S. Karapetis et al. CLINICAL CANCER RESEARCH
- A colorectal cancer classification system that associates cellular phenotype and responses to therapy
- (2013) Anguraj Sadanandam et al. NATURE MEDICINE
- Beyond KRAS mutation status: influence of KRAScopy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients
- (2012) Leonie JM Mekenkamp et al. BMC CANCER
- Loss of PTEN expression as a predictor of resistance to anti-EGFR monoclonal therapy in metastatic colorectal cancer: evidence from retrospective studies
- (2012) Zhen-Hua Wang et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phosphatase and tensin homolog expression related to cetuximab effects in colorectal cancer patients: A meta-analysis
- (2012) Yue Shen WORLD JOURNAL OF GASTROENTEROLOGY
- Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer
- (2011) E. Razis et al. BREAST CANCER RESEARCH AND TREATMENT
- Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2nd Line Cetuximab-Based Therapy of Colorectal Cancer Patients
- (2011) Zacharenia Saridaki et al. PLoS One
- Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know
- (2010) Mizuki Nishino et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
- (2008) F. Perrone et al. ANNALS OF ONCOLOGY
- Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study
- (2008) Evangelia Razis et al. BMC CANCER
- Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
- (2008) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
- (2008) Carsten Bokemeyer et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started